Product Description
Enasidenib is an inhibitor of IDH2. It is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene. The drug was discovered in 2009 by scientists at Agoios and the development names for the drug was AG-221 and CC-90007.
Enasidenib was approved by the FDA in August 2017. The trade name under which it was approved was Idhifa.
6-[6-(Trifluoromethyl)-2-pyridinyl]-1,3,5-triazine-2,4(1H,3H)-dione is one of KMS of Enasidenib, the appearance is white to off-white powder solid, the purity is not less than 98% by HPLC. the Purity of API (Enasidenib) is not less than 99.5%
![132112-67-5, Bicyclo[2.2.1]heptane-2,6-dicarbonitrile](https://www.pudeepharm.com/wp-content/uploads/2024/05/675.jpg)
![189253-72-3, (2-{2-[(3-aminopropyl)(methyl)amino]ethoxy}ethyl)dimethylamine](https://www.pudeepharm.com/wp-content/uploads/2024/05/723.jpg)
![835914-81-3, 4-[[4-[[6-[[1-Amino-8-hydroxy-7-[(4-nitro-2-sulfophenyl)azo]-4,6-disulfo-2-naphthalenyl]azo]-1-hydroxy-3,5-disulfo-2-naphthalenyl]azo]-2-chloro-6-sulfophenyl]azo]-4,5-dihydro-5-oxo-1-(4-sulfophenyl)-1H-pyrazole-3-carboxylic acid, lithium sodium salt](https://www.pudeepharm.com/wp-content/uploads/2024/05/813.jpg)
